About Us

Who we are

Medibiofarma is a Spanish clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases.
image_about_1

Mission

The discovery and development of novel, small molecule drugs

  • for the treatment of cancer, specifically through activation of the immune system.
  • for the treatment of non-cancer, target-related diseases.

Vision

To make disease-modifying treatments available to patients with serious or life-threatening conditions

How do we achieve our vision

At Medibiofarma, we are:

  • The Drug Discovery Process
  • Virtual Drug Design
  • Medicinal Chemistry
  • Intellectual Property
  • Project Management
  • Business Development
  • Raising Funds

All other activities for full characterization and development of compounds into clinical candidates, are carried out through established partnerships with contract research organizations, research centers and universities.

Leading scientists

Rodolfo Rodríguez Iglesias

Rodolfo Rodríguez Iglesias

Founder, IP director & General Manager

Rodolfo Rodríguez Iglesias is Chemical Engineer, Master in Science in Biotechnological Processes and Patent Technician. He has 15 years of experience in industrial property and 8 years as a specialist in vaccine production. With knowledge in the protection of inventions and strategies for the registration of intellectual property, drafting of patents, patent research, patentability studies, infringement studies, freedom to operate, procedures for processing and examining national and European patents, and international applications of patents, and in the biotechnological sector in fermentation, molecular biology, basic immunology, etc.

Since December 2016, he is founder and IP responsable in Medibiofarma.

 

Richard Roberts, PhD

Chief Scientific Officer

Richard holds a degree in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge, followed by a three-year post-doc at Imperial College, London.

He has 20 years’ experience in the field of medicinal chemistry and drug discovery. After a spell as Team Leader at Syngenta, UK, he moved to Almirall in Barcelona in 2002 as a Senior Medicinal Chemist. From 2008 he was Program Leader, discovering potent molecules related to asthma, cough and itch. He was also involved in a range of other activities, from open innovation and compound logistics to managing major collaborations.

Since 2016 he has been in the biotech sector, first as Director of Drug Discovery at Minoryx, a clinical-stage company focused on rare genetic disorders. He was then Director of Medicinal Chemistry at the Kærtor Foundation, a pioneer incubator for early drug discovery in collaboration with industry.

He joined Medibiofarma as Chief Scientific Officer in 2020

Horacio Moreno, PhD

Business Development Director

Horacio holds a degree in Biochemistry, and a PhD in Biochemistry and Molecular Biology from the University of Barcelona, with a postgraduate stage at the University of Heidelberg, Germany.

He started his career in Business Development and Licensing at Almirall in 2002, and since then has held different positions of increasing responsibility in this area at Almirall, Gebro Pharma and Menarini, where he was regional head for BD for Spain and Latin America. He has also collaborated with several local biotech companies and research centres, including AVX Pharma, which was sold to Aerie Pharmaceuticals in a transaction closed in 2019.

He combines this professional activity in Business Development with teaching at the University for Biotechnology students (IQS, Institut Químic de Sarriá, URL).

Horacio joined Medibiofarma as Director of Business Development in October 2021.

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the mentioned cookies and the acceptance of our Cookies policy.
. ACEPTAR

Aviso de cookies